Cytoreduction Surgical Procedures
"Cytoreduction Surgical Procedures" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Operative procedures carried out to reduce a mass of tissue, for example, to reduce the total amount of tissue composing a tumor.
| Descriptor ID |
D065426
|
| MeSH Number(s) |
E04.166
|
| Concept/Terms |
Cytoreduction Surgical Procedures- Cytoreduction Surgical Procedures
- Cytoreduction Surgical Procedure
- Procedure, Cytoreduction Surgical
- Surgical Procedure, Cytoreduction
- Debulking Surgical Procedures
- Debulking Surgical Procedure
- Procedure, Debulking Surgical
- Surgical Procedure, Debulking
- Cytoreductive Surgery
- Cytoreductive Surgeries
- Surgery, Cytoreductive
- Cytoreductive Surgical Procedures
- Cytoreductive Surgical Procedure
- Procedure, Cytoreductive Surgical
- Surgical Procedure, Cytoreductive
- Surgical Procedures, Cytoreductive
|
Below are MeSH descriptors whose meaning is more general than "Cytoreduction Surgical Procedures".
Below are MeSH descriptors whose meaning is more specific than "Cytoreduction Surgical Procedures".
This graph shows the total number of publications written about "Cytoreduction Surgical Procedures" by people in this website by year, and whether "Cytoreduction Surgical Procedures" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 4 | 5 |
| 2020 | 2 | 2 | 4 |
| 2021 | 1 | 5 | 6 |
| 2022 | 2 | 3 | 5 |
| 2023 | 0 | 8 | 8 |
| 2024 | 1 | 4 | 5 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytoreduction Surgical Procedures" by people in Profiles.
-
Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high grade serous carcinoma is dependent on chemotherapy response score. Hum Pathol. 2025 May; 159:105800.
-
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. Gynecol Oncol. 2025 Mar; 194:18-24.
-
Multisocietal Consensus on the Use of Cytoreductive Surgery and HIPEC for the Treatment of Diffuse Malignant Peritoneal Mesothelioma: A GRADE Approach for Evidence Evaluation and Recommendation. J Surg Oncol. 2025 Apr; 131(5):810-815.
-
Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2025 01; 177:108834.
-
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study. Gynecol Oncol. 2024 07; 186:17-25.
-
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy postoperative symptomatology: palliative care impact. BMJ Support Palliat Care. 2024 Jan 08; 13(e3):e872-e875.
-
ASO Visual Abstract: Fragmentation of Care in Patients with Peritoneal Metastases Undergoing Cytoreductive Surgery. Ann Surg Oncol. 2024 01; 31(1):657-658.
-
ASO Author Reflections: Fragmented Care in Patients with Peritoneal Metastases. Ann Surg Oncol. 2024 01; 31(1):655-656.
-
Fragmentation of Care in Patients with Peritoneal Metastases Undergoing Cytoreductive Surgery. Ann Surg Oncol. 2024 Jan; 31(1):645-654.
-
Doublet vs. Triplet Systemic Chemotherapy for High Grade Appendiceal Adenocarcinoma with Peritoneal Metastases. J Gastrointest Surg. 2023 11; 27(11):2560-2562.